Abstract: Chikungunya (CHIKV) is an emerging arboviral infection with recent spikes in transmission in the Americas. Chikungunya is most commonly transmitted by mosquitos, specifically Aedes aegypti and Aedes albopictus. These mosquitoes are found throughout many parts of the United States. The classic tetrad of symptoms for CHIKV is fever, symmetric polyarthralgia, maculopapular rash, and nonpurulent conjunctivitis. Although the majority (3 of 4) of infected people will be symptomatic, the viral illness generally runs a benign course. Nevertheless, when compared with infected adults, children more commonly have neurological and dermatological symptoms and are less likely to have arthralgia. The key differential diagnosis to consider is dengue, which has greater immediate morbidity and which can cause coinfection. Local health departments facilitate diagnostic testing, using either RNA polymerase chain reaction or antibody screening based on the timing of presentation. Management is supportive. The purpose of this review article is to provide readers basic knowledge regarding the microbiology, epidemiology, risk factors for transmission, and typical clinical presentation of CHIKV. A practical approach to diagnosis and management of infected children is provided. 
1. Evaluate and manage a child with suspected chikungunya (CHIKV) infection. 2. Assess the epidemiology and transmission risk factors for CHIKV. 3. Compare features that distinguish the two emerging arboviral infections CHIKV and dengue.
A rthropod-borne viruses (hence arboviruses) are responsible for some of the key emerging infectious diseases and significant health problems the world faces today. 1 Dengue virus is the most common mosquito-transmitted arbovirus. In recent years, however, there have been spikes in transmission of CHIKV and Zika viruses in the Americas. This article will focus on CHIKV and providing essential background and practical knowledge for those who might encounter this disease in a pediatric emergency setting.
There have been outbreaks of CHIKV in Africa and Asia every 2 to 20 years for the latter half of the 20th century. 2 The name CHIKV was first used in 1953 during an outbreak of fever and polyarthralgia in Tanganyika, eastern Africa. The Makonde translation for CHIKV is that which bends up, a reference to the crippling arthralgia that many patients have. 3 In the early part of the 21st century, there were multiple documented cases of CHIKV in returning travelers throughout the United States and Europe, and the Centers for Disease Control and Prevention (CDC) advised physicians to include CHIKV on their differential for fever in a returning traveler. 4 In December 2013, CHIKV gained international attention when the first local transmission in North America occurred at Oyster Pond in St Martin. 5 
EPIDEMIOLOGY
By the end of 2014, the Pan American Health Organization had reported almost 1 million cases of CHIKV in all 48 member-states. 6 In the United States there were a total of 2811 cases reported to ArboNET in 2014 (including 12 autochthonous cases, locally transmitted and not imported, from Florida). Fortyfive percent of the total national cases came from Florida and New York. 7 There were an additional 4710 cases from US territories, the vast majority of which were autochthonous cases in Puerto Rico, the US Virgin Islands, and American Samoa. 8 Provisional CDC data for 2017 show 114 cases, all in travelers returning to the United States (Fig. 1 ). 9 
MICROBIOLOGY, MODES OF TRANSMISSION, AND RISK FACTORS
Chikungunya is a small (60-70 nm), spherical, enveloped virus. 10 Chikungunya has a linear, positive sense, single-stranded 12 kb RNA genome. 2 Other examples of the same genus of alphaviruses include Eastern and Western equine encephalitis virus, Ross River virus, and Middleburg virus. 2 Chikungunya, like dengue and many other arboviruses, is capable of initiating a sustained urban transmission cycle that relies on 2 species of mosquitoes: Aedes aegypti and Aedes albopictus (also known as the tiger mosquito) with humans as the amplification host. These are the same mosquito species associated with Zika transmission. Aedes aegypti is found globally in the tropical, subtropical, and parts of the temperate world. 11 Aedes albopictus originated in Asia but is now found in a global distribution. 12 Within the United States, 1 or both species are found in most states except for the Pacific Northwest (Fig. 2) . 13 Returning travelers from areas with high levels of mosquito activity are at risk for CHIKV. The attack rate for CHIKV has been reported to be up to 60% (aided by a population in Americas that has almost no immunity). This is a higher attack rate than for dengue. 14 Mosquitoes are the most common means of transmitting CHIKV, but other modes of transmission are possible, including blood-borne. During the 2014 Caribbean outbreak, there was a high prevalence of CHIKV in donated blood samples (nucleic acid amplification test samples peaked at 2.1% in one series), but there have been no documented cases of CHIKV transmission due to transfusion. 15 In the La Reunion outbreak, there was one case of needle-stick transmitted disease. 16 Transmission across the placenta during the first and second trimester is possible although unusual, with rare cases of fetal infection and miscarriage. 17 Maternal infection within 1 week of delivery, however, carries a high risk of vertical transmission and potentially severe disease in the neonate. A single-center case series in Latin America tracked 7 women with peripartum infections who delivered 8 babies: all newborns required intensive care unit admissions, and there was a case fatality rate of 37.5%, with the neonates having complications including respiratory distress, necrotizing enterocolitis, meningoencephalitis, myocarditis, pericarditis, edema, and bullous dermatitis. 18 Paired serum testing of mothers and newborns has shown that 81% of mothers transfer antibodies to babies. 19 There are conflicting statements on whether CHIKV is transmitted in breast milk, as there are limited data. The CDC states that there have been no confirmed cases of infants acquiring CHIKV through breastfeeding and thus encourages women to continue to breastfeed even if they are infected with CHIKV or live in an area with ongoing virus transmission. 20 
CLINICAL SIGNS AND SYMPTOMS
In the United States where CHIKV is not yet endemic, a minimum case definition should be considered the acute onset of fever and polyarthralgia in travelers recently returned from areas with known virus transmission. The incubation time is 3 to 7 days (range, 1-12 days), and the majority of those infected with CHIKV become symptomatic (3 of 4 infected people in some estimates). The disease is most typically characterized by fever higher than 39°C and a severe symmetric polyarthralgia that usually resolves within 7 to 10 days (these 2 symptoms were present in 96% of confirmed cases in the La Reunion outbreak). 21 The prevalence of other symptoms in confirmed cases during this well-studied outbreak was as follows: headaches, 70%; nausea and vomiting, 63%; myalgia, 59%; exanthems, 48%; and a nonpurulent conjunctivitis, 23%. 21, 22 Thus, in contrast to the minimum case definition, the classic tetrad of symptoms is fever, symmetric polyarthralgia, maculopapular rash, and nonpurulent conjunctivitis.
More serious and rare reported complications include encephalitis, autoimmune neurological deficits (such as GuillainBarré and cranial nerve palsies), uveitis, retinitis, myocarditis, hepatitis, nephritis, and death. Atypical or severe clinical manifestations can be due to the direct effects of the virus, immunologic response to the virus, drug toxicity, or coinfection with other diseases. During the La Reunion epidemic, 0.3% of cases were defined as atypically severe (defined as requiring organ support for 1 or more organ). The case fatality ratio is low (1:1000) with most of these in very young or elderly patients or those with preexisting medical conditions. 23 In contrast to dengue, hemorrhagic complications are rare with CHIKV. Whereas symptoms typically last less than 10 days, chronic symptoms, especially arthralgia, have been reported for many months afterwards.
There are limited data on pediatric specific presentations of CHIKV. Children have been noted to have a higher rate of asymptomatic infection (up to 40%). 24 Children may also exhibit a broader range of dermatological manifestations (including bullous rashes and pigment changes). Neurological manifestations are more common in children, whereas myalgia and arthralgia are less common. These age-related differences are summarized in Table 1 . One case series from India describes 56 infants less than 1 year old with acute illness and positive laboratory testing for CHIKV immunoglobulin M (IgM). 25 All patients had fever; 39% had seizures (all had cerebrospinal fluid studies that did not suggest acute meningitis). Other features not typically described in adults included cyanosis (75%) and dermatological manifestations including generalized erythema, maculopapular rash, vesiculobullous lesions, and skin peeling. Joint findings were absent in this case series. There were no fatalities. Caution should be taken in extrapolating these findings, as it is unclear whether these differences relate to age-specific differences in the disease or strain-specific features of the local epidemic. The potential long-term sequelae for perinatally infected babies include a high risk for global developmental delay, microcephaly, and cerebral palsy. 26 Maternal infections do not appear to be more severe than in nonpregnant adult women and do not appear to cause adverse outcomes for the pregnancy. In one series of 1400 women with 658 infections (of which 15% were in the first trimester, 59% second trimester, and 26% third trimester), rates of cesarean delivery, hemorrhage, preterm births, stillbirths after 22 weeks, low birth weight, congenital anomalies, and newborn admissions were all similar for infected versus noninfected women. 27 
DIFFERENTIAL DIAGNOSES
The differential diagnoses for CHIKV vary based on place of residence, travel history, and exposures. Dengue most closely mimics CHIKV, with similar clinical features and transmission by the same mosquito. These 2 viruses can also be coinfectants. Exclusion of dengue virus infection is important, as proper clinical management of dengue can improve outcomes. Per the CDC, clinicians should consider dengue more likely when a patient has neutropenia, thrombocytopenia, hemorrhage, or shock. Chikungunya is more likely when high fever, severe arthralgia, arthritis, rash, and lymphopenia are present (Table 2 ). In addition to • Myalgia, arthralgia (30%-50%)
• Arthritis/arthralgia, symmetric, more commonly affecting distal joints (87%-99%) • Tenosynovitis (common) • Back pain (more common) • Myalgia (60%-93%) Chronic joint manifestations
• Arthralgias/arthritis persistent for 2 years (5%-11%)
• Arthralgias persistent or recurrent for 1 year in up to 57%
Hemorrhagic manifestations • Purpura, ecchymoses (10%)
• Severe bleeding from nose, gums, gut, and shock (up to 19% in neonates)
• Severe bleeding from nose, gums, gut, and shock (rare)
Neurological manifestations
• Headache (15%)
• Seizures, acute encephalopathy, meningoencephalitis (14%-32%)
• Headache (40%-81%)
• Encephalopathy, meningoencephalitis, acute flaccid paralysis, Guillain-Barré syndrome (<0.1%) Asymptomatic disease
• 35%-40% (rare in neonates and infants)
• 16%-27% dengue, other considerations include leptospirosis, malaria, rickettsia, group A streptococcus, rubella, measles, parvovirus, enteroviruses, adenovirus, other alphavirus infections (eg, Mayaro, Ross River, Barmah Forest, O'nyong-nyong, and Sindbis viruses), postinfections arthritis, and rheumatologic conditions.
DIAGNOSTIC TESTING
The preliminary diagnosis of CHIKV should be based on the patient's clinical features, places, and dates of travel, and activities. Basic nonspecific laboratory abnormalities that may increase suspicion include leukopenia (usually a lymphopenia) (38%), thrombocytopenia (37%), elevated transaminases, and hypocalcemia (39%). 30 Laboratory diagnosis is done by testing serum or plasma to detect virus, viral nucleic acid, or virus-specific IgM and neutralizing antibodies. Because the clinical features of CHIKV and dengue overlap, it is recommended to test for both infections. Note however that antibodies for one arbovirus genus can cross-react with heterologous antigens within the genus. 31 The CDC testing algorithm includes CHIKV, Zika, and dengue viruses and is outlined in Figure 3 . 32 Diagnostic testing is currently available through state health departments and the CDC. Practitioners should be familiar with the capabilities of their local and state health departments. After the onset of illness, the virus can be detected in blood and other tissues for 4 to 5 days. Viral culture may detect virus in the first 3 days of illness. Because CHIKV must be handled under biosafety level 3 conditions, this test is not recommended in the CDC algorithm. Instead, CHIKV viral-RNA can be identified using serum real-time reversetranscription polymerase chain reaction (RT-PCR) within 7 days of symptom onset. Because viremia decreases over time, a negative test after 7 days should not rule out infection. If RT-PCR is negative, clinicians sequentially test for serum IgM enzymelinked immunosorbent assay as long as the symptoms have been present for at least 4 days. If both the viral RNA test (RT-PCR) and the IgM antibody test are negative, the patient does not have CHIKV. Beyond 7 days from symptom onset, the serum IgM test is used alone. A negative IgM is sufficient to stop testing for 22, 28 , and 29 . Note that severe dengue encompasses both dengue hemorrhagic fever and dengue shock syndrome.
FIGURE 3. CDC testing algorithm for CHIKV, dengue, and Zika virus. 32 Pediatric Emergency Care • Volume 34, Number 7, July 2018 CHIKV in Children CHIKV. If the serum IgM is positive, a confirmatory test using a plaque-reducing neutralization test is performed to distinguish which of the cross-reacting viruses is causing disease. The best type of tube to collect blood samples in is a serum separator (typically tiger/speckled-top). The blood should be allowed to coagulate, and tubes should be spun to separate the serum from the clot prior to shipping. If a red top is used (no additive), the blood must be allowed to coagulate, the tube centrifuged, and the serum drawn off into a clean tube prior to shipping. Heparin (green top) and ethylenediaminetetraacetic acid tubes (purple top) are unsuitable for CHIKV testing. Chronic disease diagnosis is entirely dependent on IgG, with no validated markers of chronicity or disease progression.
MANAGEMENT
The natural history of CHIKV is the resolution of acute symptoms within 7 to 10 days. Treatment is primarily symptomatic, with no specific antiviral therapy recommended. Providers should assess hydration and hemodynamic status and provide supportive care as needed. Acetaminophen can be used for fever and pain control. If further analgesics are required, consider judicious use of narcotics. Some authors warn against indiscriminate use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) (especially aspirin) owing to the risk of platelet dysfunction increasing the risk for clinically significant hemorrhage. In addition, the overlap in symptoms with dengue infection leads to the CDC recommending against the use of NSAIDs because of the risk of hemorrhage with dengue infections.
Chikungunya virus disease is a nationally notifiable condition, meaning that health care providers should report suspected CHIKV cases to their state or local health departments to facilitate diagnosis and mitigate the risk of local transmission. To decrease autochthonous transmission, patients should be counseled to stay indoors and avoid mosquito bites during the first week when they are most likely to be viremic.
Some patients might have relapse of rheumatologic symptoms (eg, polyarthralgia, polyarthritis, and tenosynovitis) in the months after acute illness. Persistent joint pain may benefit from the use of NSAIDs, corticosteroids, or physiotherapy. Chronic arthralgia has been treated with a range of medications in small trials in both humans and animals, with mixed results. Referral to a pediatric rheumatologist would be appropriate in these cases. A number of candidate vaccines for CHIKV are currently in the preclinical and clinical stages of development. 33, 34 
CONCLUSIONS
Chikungunya has been endemic in Africa and Asia since at least the 1950s. Year 2013 marked the beginning of local spread of cases within the Americas, with more than 1 million cases documented in 2014. Chikungunya usually consists of fever and arthralgia for 7 to 10 days. Compared with adult cases, pediatric patients are more likely to have a range of acute neurological and dermatological manifestations, while being less likely to develop subacute or chronic joint problems. The treatment remains largely supportive. Testing for CHIKV exists through state health departments and the CDC including RNA and IgM. Chikungunya is a notifiable disease in the United States. Any viremic traveler with CHIKV who returns to an area in the United States with A. albopictus or aegypti mosquitoes could initiate a local outbreak. There is therefore a need to establish local processes for workup and management of such cases. Emerging infection diseases such as CHIKV require clear lines of communication between emergency department and infectious disease specialists, along with pediatricians in the community as well as local and state health departments.
